These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7795599)

  • 1. Deletion of the C-terminal end of aspartylglucosaminidase resulting in a lysosomal accumulation disease: evidence for a unique genomic rearrangement.
    Jalanko A; Manninen T; Peltonen L
    Hum Mol Genet; 1995 Mar; 4(3):435-41. PubMed ID: 7795599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the 3'-untranslated region of aspartylglucosaminidase mRNA results in a lysosomal accumulation disease.
    Ikonen E; Ulmanen I; Peltonen L
    J Biol Chem; 1992 May; 267(13):8715-8. PubMed ID: 1577713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
    Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
    Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning, chromosomal assignment, and expression of the mouse aspartylglucosaminidase gene.
    Tenhunen K; Laan M; Manninen T; Palotie A; Peltonen L; Jalanko A
    Genomics; 1995 Nov; 30(2):244-50. PubMed ID: 8586423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
    Saarela J; von Schantz C; Peltonen L; Jalanko A
    Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
    Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
    Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease.
    Riikonen A; Ikonen E; Sormunen R; Lehto VP; Peltonen L; Jalanko A
    DNA Cell Biol; 1994 Mar; 13(3):257-64. PubMed ID: 8172656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a point mutation in aspartylglucosaminidase gene: evidence for a readthrough of a translational stop codon.
    Peltola M; Chiatayat D; Peltonen L; Jalanko A
    Hum Mol Genet; 1994 Dec; 3(12):2237-42. PubMed ID: 7881426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assignment of the aspartylglucosaminidase gene (AGA) to 4q33----q35 based on decreased activity in a girl with a 46,XX,del(4)(q33) karyotype.
    Engelen J; Hamers A; Schrander-Stumpel C; Mulder H; Poorthuis B
    Cytogenet Cell Genet; 1992; 60(3-4):208-9. PubMed ID: 1505217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease.
    Ikonen E; Baumann M; Grön K; Syvänen AC; Enomaa N; Halila R; Aula P; Peltonen L
    EMBO J; 1991 Jan; 10(1):51-8. PubMed ID: 1703489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
    Banning A; Schiff M; Tikkanen R
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients.
    Enomaa NE; Lukinmaa PL; Ikonen EM; Waltimo JC; Palotie A; Paetau AE; Peltonen L
    J Histochem Cytochem; 1993 Jul; 41(7):981-9. PubMed ID: 7685790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular analysis of the aspartylglucosaminidase gene in Japanese patients with aspartylglucosaminuria].
    Yoshida K
    Nihon Rinsho; 1993 Sep; 51(9):2308-13. PubMed ID: 8411707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.
    Ikonen E; Enomaa N; Ulmanen I; Peltonen L
    Genomics; 1991 Sep; 11(1):206-11. PubMed ID: 1765378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.
    Banning A; König JF; Gray SJ; Tikkanen R
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of mutations in aspartylglucosaminuria.
    Ikonen E; Aula P; Grön K; Tollersrud O; Halila R; Manninen T; Syvänen AC; Peltonen L
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11222-6. PubMed ID: 1722323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splicing defect of the glycoasparaginase gene in two Japanese siblings with apartylglucosaminuria.
    Yoshida K; Yanagisawa N; Oshima A; Sakuraba H; Iida Y; Suzuki Y
    Hum Genet; 1992; 90(1-2):179-80. PubMed ID: 1427775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.